Scientists develop new device to treat cancer and other ailments

Image
ANI Washington D.C [USA]
Last Updated : Dec 02 2016 | 11:22 AM IST

In a recent study, scientists from The University of Texas invented a new device that could revolutionize the delivery of medicine to treat cancer as well as a host of other diseases and ailments.

Led by Lyle Hood, the study was published in the Journal of Biomedical Nanotechnology.

"The problem with most drug-delivery systems is that you have a specific minimum dosage of medicine that you need to take for it to be effective," Hood said.

Adding, "There's also a limit to how much of the drug can be present in your system so that it doesn't make you sick."

As a result of these limitations, a person, who needs frequent doses of a specific medicine is required to take a pill every day or visit a doctor for injections.

Hood's creation negates the need for either of these approaches, because it's a tiny implantable drug delivery system.

"It's an implantable capsule, filled with medicinal fluid that uses about 5000 nanochannels to regulate the rate of release of the medicine. This way, we have the proper amount of drugs in a person's system to be effective, but not so much that they'll harm that person," Hood explained.

The capsule can deliver medicinal doses for several days or a few weeks.

According to researchers, it can be used for any kind of ailment that needs a localized delivery over several days or a few weeks.

This makes it especially tailored for treating cancer, while a larger version of the device can treat diseases like HIV for up to a year.

"In HIV treatment, you can bombard the virus with drugs to the point that that person is no longer infectious and shows no symptoms," Hood said.

Adding, "The danger is that if that person stops taking their drugs, the amount of medicine in his or her system drops below the effective dose and the virus is able to become resistant to the treatments."

The capsule, however, could provide a constant delivery of the HIV-battling drugs to prevent such an outcome.

Hood noted it can also be used to deliver cortisone to damaged joints to avoid painful, frequent injections, and possibly even to pursue immunotherapy treatments for cancer patients.

"The idea behind immunotherapy is to deliver a cocktail of immune drugs to call attention to the cancer in a person's body, so the immune system will be inspired to get rid of the cancer itself," he said.

The current prototype of the device is permanent and injected under the skin but researchers are now working to collaborate on 3-D printing technology to make a new, fully biodegradable iteration of the device that could potentially be swallowed.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 02 2016 | 11:22 AM IST

Next Story